Germline and somatic mutations in prostate cancer: Implications for treatment
Authors:
- 8 May 2024
- journal article
- research article
- Published by Elsevier in Current Problems in Cancer
- Vol. 50, 101101
Abstract
No abstract availableKeywords
Funding Information
- US Department of Defense
- National Cancer Institute
- Prostate Cancer Foundation
This publication has 77 references indexed in Scilit:
- Efficacy of systemic therapies in men with metastatic castration resistant prostate cancer harboring germline ATM versus BRCA2 mutationsThe Prostate, 2021
- Tumor Frameshift Mutation Proportion Predicts Response to Immunotherapy in Mismatch Repair-Deficient Prostate CancerThe Oncologist, 2020
- Prevalence of comprehensive DNA damage repair gene germline mutations in Chinese prostate cancer patientsInternational Journal of Cancer, 2020
- Mutations in ATM, NBN and BRCA2 predispose to aggressive prostate cancer in PolandInternational Journal of Cancer, 2020
- Prevalence of Germline Variants in Prostate Cancer and Implications for Current Genetic Testing GuidelinesJAMA Oncology, 2019
- Analysis of the Prevalence of Microsatellite Instability in Prostate Cancer and Response to Immune Checkpoint BlockadeJAMA Oncology, 2019
- Exploiting DNA damage without repair: The activity of platinum chemotherapy in BRCA‐mutated prostate cancersCancer, 2017
- The association between germline BRCA2 variants and sensitivity to platinum‐based chemotherapy among men with metastatic prostate cancerCancer, 2017
- Familial Risk and Heritability of Cancer Among Twins in Nordic CountriesJAMA, 2016
- A phase 2 study of carboplatin plus docetaxel in men with metastatic hormone‐refractory prostate cancer who are refractory to docetaxelCancer, 2007